• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ:NXLIW)

0.0138 UNCHANGED
Last Price Updated: 3:18 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nexalin Technology, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
December 23, 2024
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
November 26, 2024
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology CEO Provides Letter to Shareholders
November 11, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
November 01, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
November 01, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
October 28, 2024
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients ↗
October 28, 2024
Nexalin says the study published in the Journal of Alzheimer's Disease shows DIFS may enhance cognition in mild Alzheimer's patients. 
Via Benzinga
News headline image
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
October 22, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
October 17, 2024
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study ↗
October 17, 2024
Nexalin Technology's clinical trial results highlight notable cognitive improvements in Alzheimer's patients using Deep Intracranial Frequency Stimulation technology. The study showed significant... 
Via Benzinga
News headline image
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
October 14, 2024
Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
September 05, 2024
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
July 18, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Closing of $5.2 Million Public Offering
July 01, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
June 27, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
June 20, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
June 13, 2024
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
June 06, 2024
Via ACCESSWIRE
News headline image
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
June 04, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
June 03, 2024
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
May 22, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
May 09, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
April 25, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
April 09, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
April 04, 2024
New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
April 02, 2024
Previously served as Acting General Counsel to the Department of Veterans Affairs 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
March 28, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 14, 2024
Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
March 13, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
March 06, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap